Celgene Presents Data on Crohn’s Therapy at DDW

Celgene Presents Data on Crohn’s Therapy at DDW
Celgene Corporation recently presented data regarding studies of its investigational oral antisense therapy called GED-0301 (mongersen) for the treatment of active Crohn’s disease at the Digestive Disease Week (DDW), which took place in Washington, D.C. The company conducted a double-blind, placebo-controlled, randomized, multicenter phase II trial and presented its post-hoc subgroup analysis. The clinical trial was designed to evaluate the therapy,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *